Deepak R Rao

Array ( [id] => 17357101 [patent_doc_number] => 20220017897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => GUIDE RNA FOR HSV-1 GENE EDITING AND METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 17/040796 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009385 [patent_doc_number] => 20200179535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => Optimized RPE65 Promoter and Coding Sequences [patent_app_type] => utility [patent_app_number] => 16/796439 [patent_app_country] => US [patent_app_date] => 2020-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16796439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17445360 [patent_doc_number] => 20220065865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS [patent_app_type] => utility [patent_app_number] => 17/415420 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520745 [patent_doc_number] => 20220106594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD) [patent_app_type] => utility [patent_app_number] => 17/285569 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506460 [patent_doc_number] => 20200385716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/595924 [patent_app_country] => US [patent_app_date] => 2019-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 73016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16595924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18018857 [patent_doc_number] => 20220370356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS [patent_app_type] => utility [patent_app_number] => 17/250952 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519220 [patent_doc_number] => 20220105068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 17/274948 [patent_app_country] => US [patent_app_date] => 2019-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482579 [patent_doc_number] => 20220090083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => TARGETING EGLN1 IN CANCER [patent_app_type] => utility [patent_app_number] => 17/275061 [patent_app_country] => US [patent_app_date] => 2019-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532357 [patent_doc_number] => 20220110966 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => POLYNUCLEOTIDES ENCODING VERY LONG-CHAIN ACYL-COA DEHYDROGENASE FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY [patent_app_type] => utility [patent_app_number] => 17/271401 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170747 [patent_doc_number] => 20210324417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF MUTANT GARS PROTEIN [patent_app_type] => utility [patent_app_number] => 17/271377 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883719 [patent_doc_number] => 20210169914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => NUCLEIC ACIDS AND NUCLEIC ACID ANALOGS FOR TREATING, PREVENTING, AND DISRUPTING PATHOLOGICAL POLYNUCLEOTIDE-BINDING PROTEIN INCLUSIONS [patent_app_type] => utility [patent_app_number] => 17/268654 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19550168 [patent_doc_number] => 12133860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => MicroRNA-based therapy targeted against LCP-1 positive cancers [patent_app_type] => utility [patent_app_number] => 17/266069 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 11086 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266069 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312961 [patent_doc_number] => 20210402009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => CARBON NANOTUBE COMPOSITE VECTOR HAVING SYNERGISTIC EFFECT OF PHOTOTHERMAL THERAPY AND GENE THERAPY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/291658 [patent_app_country] => US [patent_app_date] => 2019-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082392 [patent_doc_number] => 20210277398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => SMALL CELL LUNG CANCER THERAPEUTIC AGENT CONTAINING OLIGONUCLEOTIDE [patent_app_type] => utility [patent_app_number] => 17/261653 [patent_app_country] => US [patent_app_date] => 2019-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24485 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 1130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005318 [patent_doc_number] => 20220364084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 17/262052 [patent_app_country] => US [patent_app_date] => 2019-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262052 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052529 [patent_doc_number] => 20210261963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => COMPOSITION COMPRISING ANTISENSE OLIGONUCLEOTIDE AND USE THEREOF FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 17/253760 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082411 [patent_doc_number] => 20210277417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => METHODS OF TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS [patent_app_type] => utility [patent_app_number] => 17/253658 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17253658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16963231 [patent_doc_number] => 20210214730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => CYTOTOXIC FLUOROPYRIMIDINE POLYMERS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/058989 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17058989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932802 [patent_doc_number] => 20210198691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/055378 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 122235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976212 [patent_doc_number] => 20210220449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => Subcutaneous Delivery of Messenger RNA [patent_app_type] => utility [patent_app_number] => 17/055251 [patent_app_country] => US [patent_app_date] => 2019-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34900 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055251 [rel_patent_id] =>[rel_patent_doc_number] =>)